Open AccessEffect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo‐Controlled Study
Author(s) -
Gunawardhana Lhanoo,
McLean Lachy,
Punzi Henry A.,
Hunt Barbara,
Palmer Robert N.,
Whelton Andrew,
Feig Daniel I.
Publication year - 2017
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.117.006683
Subject(s) - medicine , febuxostat , hyperuricemia , ambulatory blood pressure , placebo , blood pressure , uric acid , population , diastole , ambulatory , essential hypertension , cardiology , endocrinology , alternative medicine , environmental health , pathology
Hyperuricemia is associated with hypertension, with elevated serum uric acid levels postulated to have a causal role in the development of hypertension. Consequently, serum uric acid reduction may help lower blood pressure (BP). A Phase 2, double-blind, placebo-controlled trial was conducted to assess the potential BP-lowering effects of the xanthine oxidase inhibitor febuxostat in subjects with hypertension and hyperuricemia (serum uric acid ≥0.42 mmol/L [≥7.0 mg/dL]).